Cardiology Care Articles & Analysis
9 news found
The study, published in the Journal of the American Medical Association in 2018 and conducted at the Scripps Research Translational Institute in partnership with Aetna and Janssen Pharmaceuticals, found that Zio XT-based screening was associated with increased detection of AFib, greater use of outpatient cardiology care, and a higher rate of initiation of stroke ...
ArmyCommand and General Staff College, and he served as the leader of Army Cardiology as Cardiology Consultant to the U.S. Army Surgeon General (2013 – 2017). ...
ByElucid
Santa Clara, Calif.– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the AccuCinch® Ventricular Restoration System. Currently being evaluated in the CORCINCH-HF pivotal clinical trial, the AccuCinch System ...
EchoNous, the leader in ultra-portable, AI-guided point-of-care ultrasound (POCUS) tools and software, announced that the company has partnered with Singapore-based Us2.ai, developers of machine learning-driven software that automates the analyses of echocardiographic imagery and measurements. ...
Food and Drug Administration’s (FDA) Pulmonology, Allergy, and Critical Care Division for the company’s lead product candidate, trans sodium crocetinate (TSC). Diffusion now has open INDs related to TSC with four FDA divisions-- Pulmonology, Allergy, and Critical Care; Cardiology and Nephrology; Neurology; and Oncology -- which the ...
ByCervoMed
It plays a crucial role in many inflammatory and autoimmune diseases across multiple therapy areas, including haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. In contrast, AstraZeneca's capabilities in genomics, precision medicine and oligonucleotides can be leveraged to develop medicines targeting less-frequent ...
The CorCinch early feasibility trials created foundational data that guided us to identify the patients to study in the randomized trial,” said Mark Reisman, MD, coprincipal investigator of the CorCinch-HF pivotal study and section head of Interventional Cardiology at the UW Medicine Heart Institute in Seattle. The transcatheter AccuCinch System is designed to complement ...
Santa Clara, Calif.– February 3, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of enrollment in its CorCinch HFrEF Early Feasibility Study (EFS), which is evaluating the AccuCinch® Ventricular Repair System in patients with reduced ejection ...
During the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, Santa Clara, CA-based Ancora presented interim study results from systolic heart failure patients treated with AccuCinch, a percutaneous therapy designed to improve left ventricular function. A stronger and more experienced Ancora Heart entered into the 31st Transcatheter Cardiovascular Therapeutics (TCT), ...